

# PACE

## PROVIDER BULLETIN

August 13, 2015

### **Praluent® (alirocumab) Injection**

On July 24, 2015 Praluent® (alirocumab) Injection was approved by the FDA *“for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol.”*

Claims submitted to PACE for Praluent® will deny with NCPDP 75 error indicating that a Medical Exception is required. The accompanying message will direct the Provider to call the 800-835-4080.

PACE will only consider granting a Medical Exception after supporting documentation from the prescriber is received and reviewed.

Questions may be directed to Provider Services at 1-800-835-4080.